Myra Vision, a Campbell, Calif.-based maker of a glaucoma treatment device and Shifamed portfolio company, closed its $17M Series A financings.
The financings were led by The Capital Partnership (TCP), with participation from Cormorant Asset Management and Shifamed angel investors.
Led by Robert Chang, CEO of Myra Vision is developing novel technology designed to allow safe outflow control to achieve maximum intraocular pressure (IOP) reduction while also reducing complexity and complication rates.
The company intends to use the funds to advance product development, scale infrastructure, and expand the team in order to support the development of its glaucoma treatment device.
In conjunction with the financing, the company has changed its name to Myra Vision, Inc. from Myra Medical, Inc.